ISSN: 2167-7689
Pharmaceutical Regulatory Affairs: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

BSE-Prion

Hideharu Shintani*
Faculty of Science and Engineering, Chuo University, 1-13-27, Kasuga, Bunkyo, 112-8551, Tokyo, Japan
Corresponding Author : Hideharu Shintani
Faculty of Science and Engineering, Chuo University
1-13-27, Kasuga, Bunkyo, 112-8551, Tokyo, Japan
Tel: +81425922336
Fax: +81425922336
E-mail: shintani@mail.hinocatv.ne.jp
Received May 16, 2014; Accepted May 19, 2014; Published June 05, 2014
Citation: Shintani H (2014) BSE-Prion. Pharmaceut Reg Affairs 3:e133. doi: 10.4172/2167-7689.1000e133
Copyright: © 2014 Shintani H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutical Regulatory Affairs: Open Access

Adventitious agents are those that are not inherent in the production of biopharmaceuticals. Microbial adventitious agents include viruses, bacteria, fungi, and mycoplasma. Transmissible spongiform encephalopathy (TSE) agents are also potential adventitious agents. Raw materials may contain adventitious agents. Adventitious agents can be introduced during establishment of cell lines, cell culture/ fermentation, capture and downstream processing steps, formulation/ filling, and even during drug delivery Therapeutic biotechnology products have an excellent safety record. However, the potential introduction of adventitious agents must continually be evaluated. The testing that is performed for this purpose is addressed in regulatory documents that include ICH guidelines, US. Points to Consider, and European, U.S., and Japanese Pharmacopoeia (EP,USP and JP) documents. In some cases, 9 CFR (U.S.Code of Federal Regulations) and 21 CFR, 211 and 610 are applicable.
Since biopharmaceuticals encompass many types of products, there is considerable variability in risks from adventitious agents. In all cases, however, the use of Good Manufacturing Practices (GMPs) (e.g., environmental controls, control of raw materials and personnel flow, and cleaning), suitable safety testing programs, and process validation (including viral and sometimes mycoplasma clearance evaluation) helps to ensure patient confidence in biopharmaceuticals. Some products have minimal inherent risk associated with the introduction of adventitious agents (e.g., recombinant products produced in bacteria). Other types of products, such as those used for cell or gene therapy, are often at the other end of the spectrum and may be associated with greater risk due to their inability to tolerate rigorous processing conditions. Greater potential risks are often associated with the use of human cells and anima1-derived raw materials. Of particular concern are materials derived from bovine and porcine sources. When viable cells are a component of the product (as in ex vivo transduction), there may not be sufficient time to perform the required safety testing. In such cases, product may be released prior to completion of relevant tests for adventitious agents, although this testing is still mandated in order to demonstrate that the processes are being performed under adequate controls to maintain patient safety. A risk/benefit analysis determines whether the use of these products is warranted. We need to prevent and control of risks arising from various stages of production. We must confirm that several risks are associated with various sources and must not overlook the risks associated with several sources.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11159
  • [From(publication date):
    October-2014 - Jul 25, 2016]
  • Breakdown by view type
  • HTML page views : 7432
  • PDF downloads :3727
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version